Elimination diets for eosinophilic esophagitis: making the best choice.

Atopy patch test diet dietary therapy elemental diet empiric elimination diet eosinophilic esophagitis food allergy skin prick test test-directed elimination diet treatment

Journal

Expert review of clinical immunology
ISSN: 1744-8409
Titre abrégé: Expert Rev Clin Immunol
Pays: England
ID NLM: 101271248

Informations de publication

Date de publication:
07 2020
Historique:
pubmed: 31 7 2020
medline: 27 8 2021
entrez: 31 7 2020
Statut: ppublish

Résumé

Dietary elimination therapy has long been an option for patients with eosinophilic esophagitis (EoE). Multiple diets have been reported, with variable efforts involved, efficacy rates, costs, and long-term management plans. Although the pros and cons of dietary elimination therapy have been described, a clear method for deciding on who is the right candidate for a diet, and which diet is best for that candidate, has not been clearly delineated. This article covers the benefits and challenges of dietary elimination therapies for patients with EoE. It outlines factors to consider before opting for an elimination diet, and for choosing which specific elimination diet to follow. Efficacy rates and pros and cons of each specific elimination diet are also discussed. Peer-reviewed published studies testing various elimination diets in patients with EoE were used for that purpose. Dietary elimination therapy is a long-term management option for patients with EoE. Shared decision making involving the patient and the medical provider is important. Multiple factors including demographics, diet, nutritional status, social and financial support, and acceptance of multiple endoscopies need to be considered. Ongoing multi-disciplinary support during the initiation and maintenance phases of the diet is crucial to ensure good outcomes.

Identifiants

pubmed: 32729737
doi: 10.1080/1744666X.2020.1801419
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

679-687

Subventions

Organisme : NIAID NIH HHS
ID : U54 AI117804
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI140133
Pays : United States

Auteurs

Mirna Chehade (M)

Mount Sinai Center for Eosinophilic Disorders, Icahn School of Medicine at Mount Sinai , New York, NY, USA.

Shimron Brown (S)

Mount Sinai Center for Eosinophilic Disorders, Icahn School of Medicine at Mount Sinai , New York, NY, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH